virus
frequent
caus
respiratori
infect
viral
respiratori
infect
signific
caus
hospit
morbid
sometim
mortal
varieti
patient
popul
lung
inflamm
induc
infect
common
respiratori
pathogen
influenza
respiratori
syncyti
viru
accompani
increas
lung
product
prostaglandin
leukotrien
lipid
mediat
wide
rang
effect
host
immun
function
defici
pharmacolog
inhibit
prostaglandin
leukotrien
product
often
result
dampen
inflammatori
respons
acut
infect
respiratori
viru
mediat
may
therefor
serv
appeal
therapeut
target
diseas
caus
respiratori
viral
infect
virus
frequent
caus
respiratori
infect
human
estim
virus
caus
lower
respiratori
infect
lri
hospit
children
less
year
age
hospit
children
age
year
among
common
caus
viral
respiratori
infect
children
adult
respiratori
syncyti
viru
rsv
influenza
rhinoviru
rv
adenoviru
parainfluenza
viru
piv
human
metapneumoviru
hmpv
viral
respiratori
infect
also
caus
substanti
diseas
burden
elderli
immunocompromis
popul
host
immun
system
face
task
effect
clear
viru
limit
local
tissu
damag
inflamm
immun
respons
virus
protect
aid
clearanc
viru
lung
resolut
diseas
caus
viral
replic
diseas
associ
respiratori
virus
also
caus
immunemedi
patholog
virusinduc
inflamm
detriment
host
caus
symptom
acut
infect
lead
damag
contribut
longterm
residu
lung
diseas
eicosanoid
potent
lipid
mediat
play
role
mani
biolog
process
includ
inflamm
immun
function
two
class
eicosanoid
prostaglandin
pg
leukotrien
lt
increasingli
studi
context
respiratori
viral
infect
effect
eicosanoid
like
make
signific
contribut
pathogenesi
respiratori
viru
infect
prostaglandin
pg
gener
phospholipas
pla
releas
arachidon
acid
aa
membran
glycerophospholipid
figur
releas
aa
oxid
intermedi
prostaglandin
h
pgh
cyclooxygenas
cox
cox
exist
three
isoform
gener
constitut
express
express
rapidli
induc
growth
factor
cytokin
recent
discov
isoform
whose
biolog
role
remain
poorli
understood
form
pgh
convert
specif
synthas
thromboxan
txa
pgd
pge
pgf
pgi
describ
pge
multipl
effect
host
immun
function
pge
transport
cell
multidrug
resist
protein
mrp
possibl
unknown
transport
effect
pge
mediat
signal
four
distinct
g
proteincoupl
e
prostanoid
ep
receptor
receptor
coupl
unidentifi
g
protein
mediat
pge
induc
increas
intracellular
ca
receptor
mediat
increas
cyclic
amp
camp
concentr
coupl
four
isoform
receptor
coupl
differ
g
protein
although
major
receptor
signal
pathway
involv
adenyl
cyclas
inhibit
via
coupl
subsequ
decreas
intracellular
camp
receptor
express
almost
mous
tissu
express
restrict
sever
organ
includ
lung
express
least
abund
ep
receptor
howev
sever
stimuli
induc
express
lt
also
gener
liber
aa
cell
membran
figur
modifi
seri
enzym
begin
act
concert
protein
flap
form
leukotrien
lta
lta
metabol
lta
hydrolas
form
leukotrien
b
ltb
altern
lta
conjug
reduc
glutathion
leukotrien
c
ltc
synthas
form
ltc
ltc
export
cell
specif
transport
act
extracellular
peptidas
form
ltd
lte
leukotrien
c
e
collect
known
cysteinyl
leukotrien
cyslt
express
tightli
regul
primarili
restrict
cell
myeloid
lineag
monocytesmacrophag
mast
cell
eosinophil
neutrophil
although
lt
synthesi
thought
restrict
leukocyt
subsequ
shown
human
bronchial
epitheli
cell
fibroblast
capabl
produc
cyslt
ltb
addit
intermedi
lta
transfer
activ
donor
cell
recipi
cell
lta
metabol
either
ltb
ltc
lta
hydrolas
ltc
synthas
respect
process
term
transcellular
biosynthesi
enzym
express
tissu
way
cell
type
epitheli
cell
becom
import
sourc
lt
inflammatori
respons
like
pge
effect
lt
mediat
signal
g
proteincoupl
receptor
among
receptor
cyslt
two
thoroughli
character
receptor
bind
ltd
high
affin
bind
ltc
lte
lower
affin
receptor
bind
ltc
ltd
equal
affin
number
studi
allud
exist
addit
cysltr
subtyp
although
yet
character
chemoattract
proinflammatori
effect
ltb
mediat
highaffin
b
leukotrien
receptor
second
receptor
b
leukotrien
receptor
bind
ltb
lower
affin
biolog
function
remain
poorli
understood
studi
transfect
cell
line
shown
four
lt
receptor
coupl
q
protein
decreas
camp
increas
intracellular
ca
respect
studi
primari
cell
yield
differ
result
specif
signal
program
initi
gpcr
remain
dissect
within
human
lung
mrna
express
epitheli
cell
bronchial
smooth
muscl
cell
interstiti
macrophag
nasal
mucosa
express
bronchial
smooth
muscl
cell
interstiti
macrophag
nasal
mucosa
human
express
primarili
leukocyt
express
alter
respons
variou
inflammatori
stimuli
express
ubiquit
high
mrna
express
detect
spleen
low
level
human
tissu
includ
lung
prostaglandin
e
pge
regul
immun
function
myriad
way
like
affect
viral
pathogenesi
tabl
widespread
express
demonstr
airway
epitheli
resid
inflammatori
cell
absenc
overt
inflamm
suggest
role
regul
human
airway
homeostasi
high
concentr
cox
product
present
epitheli
line
fluid
human
airway
potenti
play
role
inhibit
lymphocyt
activ
fibroblast
prolifer
absenc
inflamm
addit
constitut
secret
pge
airway
epitheli
cell
contribut
modul
dc
homeostat
condit
pge
promot
inflamm
vasodilatori
mechan
yield
edema
warmth
erythema
passiv
leukocyt
recruit
howev
pge
also
capabl
inhibit
neutrophil
chemotaxi
phagocytosi
bacteri
kill
pge
suppress
phagocytosi
nonalveolar
monocytesmacrophag
pge
inhibit
alveolar
macrophag
phagocytosi
via
mechan
involv
activ
increas
camp
bacteri
kill
reactiv
oxygen
intermedi
gener
am
also
inhibit
pge
campdepend
manner
product
variou
proinflammatori
cytokin
chemokin
inhibit
presenc
pge
product
antiinflammatori
cytokin
interleukin
il
enhanc
pge
suppress
product
cytokin
interferon
ifn
lead
environ
howev
number
studi
also
report
pge
mediat
enhanc
cytokin
secret
differenti
vivo
role
pge
strictli
suppress
shown
promot
certain
pathway
immun
differenti
exampl
pge
act
uncommit
b
lymphocyt
promot
isotyp
switch
ige
cox
inhibitor
inhibit
antibodi
product
activ
human
b
lymphocyt
pge
augment
product
differenti
increas
product
cell
dendrit
cell
activ
like
occur
via
increas
camp
addit
pge
enhanc
product
proinflammatori
cytokin
leukocyt
airway
epitheli
cell
pge
potent
inhibit
product
number
antimicrobi
peptid
amp
human
epitheli
cell
effect
pge
like
relev
viral
pathogenesi
amp
inhibit
replic
virus
divers
effect
lt
innat
immun
review
elsewher
briefli
summar
tabl
ltb
promot
neutrophil
migrat
surviv
enhanc
neutrophil
granul
enzym
secret
superoxid
anion
gener
lymphocyt
recruit
site
inflamm
induc
ltb
addit
neutrophil
cell
traffick
ltb
promot
migrat
dendrit
cell
dc
vitro
drain
lymph
node
mice
defici
show
reduc
dc
migrat
cyslt
ltb
enhanc
receptormedi
phagocytosi
am
though
differ
mechan
ltb
induc
antimicrobi
peptid
releas
neutrophil
vivo
case
inhibit
viral
replic
lung
gener
proinflammatori
cytokin
enhanc
ltb
number
studi
report
ltb
act
synergist
induc
activ
prolifer
differenti
human
b
lymphocyt
although
separ
studi
report
inhibitor
actual
enhanc
b
lymphocyt
prolifer
cyslt
promot
microvascular
leak
enhanc
leukocyt
surviv
induc
nitric
oxid
gener
neutrophil
cyslt
induc
dc
chemotaxi
dc
traffick
lymph
node
impair
ltc
transporterdefici
mice
addit
cyslt
suggest
play
role
allergeninduc
dc
migrat
blood
addit
ltd
activ
b
lymphocyt
lead
modest
upregul
ige
igg
product
cyslt
also
play
role
regul
pulmonari
respons
mice
defici
ltc
synthas
show
reduc
cytokin
mrna
express
agspecif
ige
lung
cyslt
recogn
import
mediat
pathogenesi
asthma
abil
promot
airway
microvascular
permeabl
mucu
secret
smooth
muscl
contract
prostaglandin
leukotrien
modul
mani
host
immun
respons
import
contributor
viral
pathogenesi
cytokin
signal
neutrophil
macrophag
phagocytosi
traffick
activ
dc
cell
antibodi
product
b
cell
influenza
influenza
infect
account
hospit
annual
usa
addit
hospit
influenza
also
associ
substanti
number
outpati
visit
year
caus
consider
healthcar
burden
econom
cost
influenza
upregul
express
vitro
vivo
suggest
cox
hyperinduct
contribut
exagger
cytokin
respons
observ
sever
human
infect
alter
cox
pathway
contrast
effect
inflammatori
respons
influenza
viru
depend
model
pharmacolog
inhibit
dual
inhibit
genet
defici
treatment
influenzainfect
mice
celecoxib
select
inhibitor
significantli
affect
viral
titer
diseas
sever
although
treatment
suppress
product
lung
proinflammatori
cytokin
tumor
necrosi
factor
tnf
granulocytecoloni
stimul
factor
gcsf
contrast
influenza
infect
mice
genet
defici
result
reduc
mortal
inflamm
cytokin
respons
compar
infect
wildtyp
control
peak
lung
viral
titer
significantli
elev
mice
return
level
seen
wildtyp
mice
day
suggest
role
control
earli
viral
replic
viru
clearanc
interestingli
level
pge
influenzainfect
mice
equival
level
measur
infect
wildtyp
mice
lack
pge
defici
mice
could
due
compensatori
upregul
activ
describ
mice
infect
highli
virul
treat
combin
celecoxib
neuraminidas
inhibitor
zanamivir
mesalazin
aminosalicyl
drug
exhibit
weak
cox
inhibit
show
significantli
improv
surviv
even
treatment
delay
hour
benefici
effect
celecoxib
mesalazin
like
stem
effect
immunopatholog
mice
treat
tripl
therapi
similar
viral
load
treat
zanamivir
alon
tripl
therapi
significantli
reduc
level
proinflammatori
cytokin
anoth
group
treat
influenzainfect
mice
paracetamol
acetominophen
select
inhibitor
paracetamoltr
mice
improv
lung
function
reduc
immunopatholog
compar
control
mice
separ
group
mice
treat
celecoxib
also
show
improv
cellular
infiltr
lung
function
patholog
howev
degre
improv
gener
less
seen
paracetamoltr
mice
contrast
mice
genet
defici
paracetamoland
celecoxibtr
mice
viral
load
equival
untreat
control
mice
virusspecif
cell
number
alter
treat
mice
treatment
paracetamol
celecoxib
interfer
establish
protect
immun
second
infect
differ
influenza
subtyp
significantli
increas
viral
titer
seen
mice
observ
mice
treat
inhibitor
could
due
function
defect
innat
immun
cox
product
known
involv
modul
innat
immun
respons
addit
mice
complet
loss
activ
wherea
mice
treat
inhibitor
still
retain
activ
due
insuffici
inhibit
drug
mice
level
pge
bronchoalveolar
lavag
bal
fluid
similar
wildtyp
mice
suggest
effect
defici
model
may
due
lack
pge
defici
like
affect
product
prostaglandin
txa
pgd
pgf
pgi
possibl
decreas
level
one
cox
product
respons
increas
surviv
influenza
infect
upregul
express
andor
level
lt
cell
line
well
lung
infect
mice
human
howev
studi
examin
influenza
infect
context
alter
product
either
due
genet
defici
pharmacolog
inhibit
one
studi
report
benefici
effect
exogen
ltb
administr
influenza
infect
mice
mice
treat
daili
ltb
significantli
reduc
lung
viral
load
lung
ltb
treat
mice
show
increas
level
multipl
antimicrobi
peptid
decreas
inflammatori
cell
infiltr
partial
restor
lung
architectur
antivir
effect
ltb
mediat
neutrophil
highaffin
receptor
viral
load
unaffect
neutrophildeplet
mice
ltb
treatment
primari
human
neutrophil
studi
induc
antimicrobi
peptid
releas
decreas
influenza
titer
demonstr
effect
ltb
neutrophil
similar
mice
human
agreement
anoth
studi
human
mediat
inflamm
neutrophil
treat
ltb
show
significantli
myeloperoxidas
mpo
activ
product
untreat
cell
ltb
treat
neutrophil
enhanc
virucid
activ
influenza
viru
human
coronaviru
rsv
role
cyslt
influenza
infect
yet
defin
detail
enhanc
level
cyslt
seen
mice
infect
influenza
associ
increas
surviv
whether
decreas
mortal
mice
directli
due
cyslt
model
unknown
benefici
effect
defici
may
also
due
shunt
releas
aa
pathway
number
report
suggest
cox
inhibitor
enhanc
product
lt
inde
mice
show
higher
bal
fluid
level
cyslt
wildtyp
mice
follow
infect
influenza
howev
mice
treat
combin
zanamivir
celecoxib
mesalazin
increas
surviv
associ
lower
lt
level
higher
pge
level
treat
mice
compar
wild
type
discrep
cox
product
model
may
reflect
differ
pathophysiolog
influenza
strain
use
perhap
increas
lt
product
sever
infect
promot
inflamm
local
tissu
damag
pge
provid
balanc
protect
influenc
contrast
infect
less
virul
viru
enhanc
lt
product
may
contribut
viru
clearanc
without
detriment
effect
host
inflamm
howev
case
either
viru
lower
level
proinflammatori
cytokin
correl
decreas
morbid
increas
surviv
differ
studi
could
account
differ
viru
subtyp
viru
inoculum
mous
strain
drug
dose
deliveri
method
howev
partial
cox
inhibit
pharmacolog
intervent
appear
benefici
reduc
immunopatholog
still
control
viral
replic
influenza
infect
mice
rsv
also
signific
pathogen
elderli
popul
particularli
live
longterm
care
facil
underli
cardiopulmonari
diseas
immunocompromis
risk
sever
rsv
infect
mortal
rate
report
rsv
pneumonia
rsv
induc
pge
releas
vitro
anim
model
lung
infant
rsv
bronchiol
treatment
cox
inhibitor
reduc
rsv
replic
vitro
diminish
immunopatholog
vivo
block
pg
product
celecoxib
cpla
inhibitor
pyrrophenon
reduc
viru
particl
product
airway
epitheli
cell
line
cox
inhibit
also
reduc
transcript
product
proinflammatori
cytokin
rant
rsvinduc
activ
interferon
regulatori
factor
irf
activ
suppress
high
concentr
celecoxib
anoth
studi
demonstr
nonselect
cox
inhibitor
indomethacin
decreas
lung
histopatholog
rsvinfect
cotton
rat
cox
inhibit
significantli
affect
viral
replic
rsv
also
induc
product
ltb
cyslt
anim
model
infant
afflict
rsv
bronchiol
lt
concentr
rsv
infect
correl
develop
symptom
report
associ
diseas
sever
treatment
rsvinfect
mice
inhibitor
zileuton
reduc
inflammatori
cell
number
lung
prevent
rsvinduc
weight
loss
decreas
rsvinduc
airway
constrict
viral
titer
somewhat
lower
lung
zileutontr
mice
although
differ
statist
signific
even
administ
emerg
respiratori
symptom
zileuton
reduc
airway
resist
weight
loss
compar
untreat
mice
treatment
antagonist
decreas
rsvinduc
airway
hyperreact
ahr
contrast
treatment
zileuton
affect
inflammatori
cell
recruit
product
rsvinfect
mice
possibl
effect
viral
titer
examin
studi
similar
highli
virul
influenza
success
treatment
rsv
infect
may
requir
use
antivir
agent
combin
antiinflammatori
agent
limit
immunopatholog
support
treatment
rsvinfect
cotton
rat
rsvspecif
human
monoclon
antibodi
palivizumab
glucocorticoid
result
enhanc
clearanc
rsv
limit
lung
histopatholog
compar
control
support
come
model
pneumonia
viru
mice
pvm
paramyxoviru
close
phylogenet
rel
rsv
pvm
infect
increas
level
cyslt
lung
model
administr
either
antagonist
montelukast
nucleosid
analog
ribavirin
affect
diseas
sever
howev
combin
therapi
montelukast
ribavirin
substanti
decreas
morbid
mortal
pvminfect
mice
administr
montelukast
primari
rsv
infect
prevent
enhanc
ahr
airway
eosinophil
recruit
mucu
overproduct
upon
reinfect
montelukast
administ
secondari
infect
affect
enhanc
respons
previou
studi
shown
lt
transient
elev
acut
phase
infect
level
drop
baselin
shortli
suggest
lt
inhibitor
may
benefici
effect
earli
phase
infect
may
longer
use
treatment
longterm
airway
dysfunct
observ
rsv
infect
lt
level
longer
elev
report
demonstr
benefici
effect
product
inhibitor
receptor
antagonist
primari
infect
rsv
howev
studi
anim
model
use
pharmacolog
agent
given
mice
start
day
infect
wherea
treatment
human
typic
initi
later
cours
infect
emerg
symptom
delay
zileuton
treatment
day
post
infect
respiratori
symptom
emerg
still
reduc
clinic
sign
primari
rsv
infect
mediat
inflamm
mice
howev
conflict
result
inhibitor
cyslt
antagonist
use
treatment
children
rsv
bronchiol
one
studi
suggest
benefici
effect
antagonist
montelukast
lung
symptom
rsv
bronchiol
studi
fail
corrobor
find
knowledg
human
studi
examin
prophylact
administr
pathway
inhibitor
receptor
antagonist
highrisk
children
studi
need
defin
role
lt
inhibitor
patient
primari
rsv
infect
experienc
persist
airway
dysfunct
rsv
mani
virus
capabl
caus
respiratori
infect
rel
littl
known
contribut
made
eicosanoid
pathogenesi
respiratori
virus
influenza
rsv
rhinoviru
rv
infect
increas
express
flap
human
bronchial
cell
addit
cyslt
level
bal
fluid
increas
upon
rhinoviru
infect
human
correl
emerg
upper
respiratori
symptom
adenoviru
induc
express
pge
releas
murin
fibroblast
human
primari
synovi
fibroblast
addit
studi
necessari
examin
adenovirusinduc
pg
product
lungrelev
cell
type
vivo
studi
human
adenoviru
pathogenesi
limit
strict
speci
specif
adenovirus
use
mous
adenoviru
type
studi
pathogenesi
adenoviru
respiratori
infect
provid
use
tool
defin
role
eicosanoid
adenoviru
respiratori
infect
human
cytomegaloviru
hcmv
also
caus
respiratori
infect
although
symptomat
diseas
uncommon
immunocompet
individu
hcmv
induc
express
ltb
product
vascular
smooth
muscl
cell
well
express
pge
product
fibroblast
inhibit
reduc
level
immediateearli
mrna
protein
addit
viral
dna
replic
transcript
earli
late
mrna
treatment
hcmvinfect
fibroblast
cox
inhibitor
inhibit
celltocel
spread
viru
note
mani
report
virus
shown
inhibit
viral
replic
gene
transcript
cox
inhibitor
nonphysiolog
concentr
result
hcmv
obtain
concentr
cox
inhibitor
achiev
human
plasma
although
studi
examin
effect
product
hcmv
pathogenesi
one
studi
report
exogen
ltb
inhibit
reactiv
cmv
follow
allogen
bone
marrow
transplant
bmt
mice
demonstr
benefici
effect
lt
data
summar
see
also
tabl
clear
effect
cox
inhibit
antagon
cyslt
receptor
host
respons
respiratori
viral
infect
variabl
case
may
pathogenandor
modelspecif
gener
cox
inhibit
defici
associ
less
exuber
inflamm
case
improv
surviv
cox
product
may
play
role
control
earli
viral
replic
although
possibl
role
evid
influenza
infect
mice
complet
lack
activ
mice
treat
inhibitor
data
consist
role
pge
immunomodulatori
mediat
balanc
proinflammatori
action
suppress
effect
innat
adapt
immun
function
inhibit
lt
product
signal
respiratori
viral
infect
associ
less
inflamm
accompani
variabl
gener
benefici
effect
lung
physiolog
howev
administr
exogen
ltb
also
blunt
inflammatori
respons
influenza
viru
one
studi
suggest
variou
product
may
differenti
involv
promot
inflamm
affect
host
immun
respons
viral
infect
respiratori
viral
infect
caus
substanti
diseas
associ
signific
morbid
mortal
healthcar
util
mani
antivir
drug
avail
treat
infect
human
immunodefici
viru
smaller
number
drug
acyclovir
ganciclovir
avail
treat
infect
herpesvirus
herp
simplex
viru
varicella
zoster
viru
hcmv
contrast
far
fewer
drug
avail
treat
virus
frequent
caus
respiratori
infect
neuraminidas
inhibitor
oseltamivir
zanamavir
use
prophylaxi
prevent
infect
influenza
viru
use
treat
infect
older
drug
amantadin
rimantadin
also
use
prevent
treat
influenza
howev
emerg
drugresist
influenza
strain
potenti
increasingli
limit
util
drug
nucleosid
analog
cidofovir
use
treat
adenoviru
infect
although
substanti
toxic
random
clinic
trial
perform
show
clinic
benefit
current
drug
consist
shown
safe
effect
treatment
diseas
caus
infect
rsv
rhinoviru
human
metapneumoviru
virus
commonli
caus
respiratori
infect
prevent
virusinduc
inflamm
may
serv
import
adjunct
antivir
therapi
antivir
drug
avail
modul
virusinduc
inflamm
may
serv
effect
strategi
treat
diseas
caus
virus
drug
abil
modul
eicosanoid
product
ibuprofen
acetaminophen
alreadi
frequent
use
patient
respiratori
infect
allevi
fever
myalgia
nonspecif
symptom
studi
describ
show
decreas
virusinduc
inflamm
increas
surviv
anim
treat
inhibitor
pg
lt
synthesi
pgor
ltdefici
anim
support
potenti
benefit
approach
drug
modul
eicosanoid
product
may
particularli
use
prevent
treat
infect
patient
exagger
eicosanoid
product
baselin
instanc
exagger
pge
product
set
bone
marrow
transplant
suppress
virusinduc
cytokin
product
mice
treat
celecoxib
increas
viral
titer
lung
mice
compar
control
improv
surviv
reduc
proinflammatori
cytokin
level
mice
treat
zanamivir
celecoxib
mesalazin
improv
lung
function
reduc
immunopatholog
mice
treat
paracetamol
associ
increas
suscept
bacteri
infect
link
impair
neutrophil
macrophag
phagocytosi
kill
increas
pge
product
report
human
varieti
diseas
state
includ
cancer
age
hiv
infect
malnutrit
stem
cell
solid
organ
transplant
recipi
make
potenti
benefit
approach
widespread
therapi
involv
modul
eicosanoid
product
must
consid
potenti
deleteri
effect
develop
adapt
immun
subsequ
protect
secondari
infect
pge
play
import
role
optim
antibodi
synthesi
cox
inhibitor
reduc
antibodi
product
activ
human
b
lymphocyt
addit
mice
genet
defici
produc
significantli
less
igm
igg
wildtyp
mice
evid
play
role
potenti
antibodi
product
human
well
human
volunt
challeng
rv
show
increas
nasal
symptom
suppress
serum
neutral
antibodi
respons
treat
aspirin
acetaminophen
suggest
protect
role
cox
product
reduc
symptom
promot
antibodi
respons
one
largescal
studi
perform
children
administ
prophylact
paracetamol
receiv
routin
childhood
vaccin
antibodi
respons
sever
vaccin
antigen
less
robust
patient
receiv
prophylact
paracetamol
evid
also
exist
lt
like
pge
promot
appropri
antibodi
respons
effect
inhibitor
receptor
antagonist
antibodi
product
yet
describ
eicosanoid
modul
mani
host
immun
respons
import
contributor
viral
pathogenesi
essenti
better
defin
mechan
underli
effect
eicosanoid
innat
adapt
immun
respons
respiratori
viral
infect
order
develop
therapi
maxim
antiinflammatori
benefit
minim
impact
protect
immun
respons
instanc
use
specif
receptor
agonist
antagonist
may
eventu
provid
bettertailor
approach
inhibitor
pg
lt
synthesi
treat
patient
respiratori
viral
infect
gener
term
howev
alter
eicosanoid
product
antagon
eicosanoid
receptor
potenti
serv
use
treatment
strategi
respiratori
viral
infect
